Disclosed are compounds inhibiting the conversion of aKG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compounds and pharmaceutical compositions can effectively treat IDH associated diseases, including cancer.